<DOC>
	<DOC>NCT02632448</DOC>
	<brief_summary>The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.</brief_summary>
	<brief_title>A Study of LY2880070 in Patients With Advanced or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale Have an estimated life expectancy of greater than or equal to (â‰¥)12 weeks Have adequate organ function Have received 14 prior standard anticancer therapies Agree to use medically approved contraceptives during the study and for 3 months following the last study treatment Females with childbearing potential must have a negative serum pregnancy test result, and a negative urine pregnancy test result, prior to the first study treatment Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Must be, in the judgment of the investigator, an appropriate candidate for experimental therapy, and no standard therapy would confer clinical benefit For Part A Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain tumor) that is advanced or metastatic For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450 (CYP2D6) poor metabolizer phenotype For Part B Have advanced or metastatic colorectal cancer, triple negative breast cancer (per American Society of Clinical OncologyCollege of American Pathology guidelines), or epithelial ovarian cancer Participants with ovarian cancer: Must be eligible to receive Gemcitabine (GEM) and not refractory to GEM/carboplatin May have received GEM as previous therapy under some circumstances, but must have completed the last GEM regimen at least 12 months prior to this study Have received treatment with an investigational drug which has not received regulatory approval within 21 days of first study treatment Have symptomatic central nervous system (CNS) metastasis Females who are pregnant or nursing Have known positive test results of human immunodeficiency virus, or have chronic active hepatitis A, B or C Have a corrected QT interval (QTcB) greater than (&gt;) 470 milliseconds (msec) (female) or &gt;450 msec (male), or a history of congenital long QT syndrome Have had a bone marrow transplant Have participated in this study, or are currently enrolled in another clinical study of an investigational medicinal product Have had radiation therapy to &gt;25% of bone marrow For Part B Have a history of another active cancer within the past year, except cervical cancer in situ, in situ carcinoma of the bladder, basal cell carcinoma of the skin, or another in situ carcinoma that is considered cured</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Recurrent cancer</keyword>
	<keyword>Colorectal neoplasms</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Ovarian neoplasms</keyword>
	<keyword>Colon neoplasms</keyword>
	<keyword>Rectal neoplasms</keyword>
	<keyword>Triple negative breast neoplasms</keyword>
</DOC>